SAC Capital Advisors’s Pfizer PFE Stock Holding History

SAC Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-843,200	Closed	-$22.4M	–	1902
2013 Q2	$22.4M	Buy	+843,200	New	+$23.3M	0.12%	223

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

SAC Capital Advisors's PFE Position: Q2 2014 in Review

SAC Capital Advisors sold out of Pfizer (PFE) in Q2 2014, closing a stake of 311,736 shares — an estimated $9.5M sold.

SAC Capital Advisors first reported a position in PFE in Q2 2013 and held it in 4 quarters. The position peaked at $47.2M in Q2 2013. 1,746 funds tracked by Wall St. Rank hold PFE as of Q2 2014.

SAC Capital Advisors reported no remaining Pfizer position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 311,736 Pfizer shares in Q2 2014, an estimated $9.5M.
SAC Capital Advisors first reported a position in Pfizer in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's Pfizer position peaked at $47.2M in Q2 2013.
1,746 funds tracked by Wall St. Rank held Pfizer as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.